Histochemical and cytochemical methods for detecting ntrk fusion proteins
AssigneeVentana Medical Systems, Inc.
InventorsJanine Feng, Frances Hansen, Linda Kivi, Patricia Nuzzo, John Palting, John Pate
Life of this patent
Estimating the term…
Loading patent…
AssigneeVentana Medical Systems, Inc.
InventorsJanine Feng, Frances Hansen, Linda Kivi, Patricia Nuzzo, John Palting, John Pate
Estimating the term…
Materials and methods for detecting NTRK rearrangements via affinity staining. Samples are stained with a biomarker-specific reagent (such as an antibody) that binds to a retained portion of TrkA, TrkB, and/or TrkC. The staining pattern is evaluated, and the presence of a Trk fusion is determined by detecting whether or not the sample has at least a threshold number of cells having a threshold staining intensity. In some cases, the same scoring methodology is applied regardless of the staining localization pattern. In other cases, a cytoplasmic and/or membranous localization is scored by a first methodology, whereas a nuclear localization is scored by a second methodology. The methods disclosed herein may be applied across non-endocrine solid tumor types.
The method of detecting a fusion protein of TrkA, TrkB, or TrkC in a non-neuroendocrine tumor sample, the method comprising:
Dependencies are inferred from the claim text.